ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,509.01
      0.62%
      US Tech 100
      19,460.00
      0.95%
      Dow Jones
      39,331.85
      0.41%
      Brent Oil
      86.485
      0.05%
      Bitcoin
      60,877.26
      -1.86%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Gilead Sciences Inc (GILD) Quote

      Gilead Sciences Inc

      Gilead Sciences Inc (GILD)

      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      DMG Mori AG
      Guild Esports Plc
      68.40
      -0.24
      (-0.35%)
      Closed July 03 4:00PM
      Delayed by 15 minutes
      68.42
      0.02
      (0.03%)
      After Hours: 7:57PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      68.42
      Bid
      68.30
      Ask
      69.00
      Volume
      4,846,200
      67.58 Day's Range 68.49
      62.07 52 Week Range 87.865
      Market Cap
      85.216B
      Previous Close
      68.64
      Open
      68.3001
      Last Trade
      5
      @
      68.49
      Last Trade Time
      Financial Volume
      $ 329,918,096
      VWAP
      68.0777
      Average Volume (3m)
      7,793,578
      Shares Outstanding
      1,245,853,209
      Dividend Yield
      4.44%
      PE Ratio
      15.04
      Earnings Per Share (EPS)
      4.55
      Revenue
      27.12B
      Net Profit
      5.67B

      About Gilead Sciences Inc

      Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmon... Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition and pending Forty-Seven acquisition boost Gilead's exposure to cell therapy and noncell therapy in oncology. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.gilead.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Gilead Sciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker GILD. The last closing price for Gilead Sciences was $68.64. Over the last year, Gilead Sciences shares have traded in a share price range of $ 62.07 to $ 87.865.

      Gilead Sciences currently has 1,245,853,209 shares outstanding. The market capitalization of Gilead Sciences is $85.22 billion. Gilead Sciences has a price to earnings ratio (PE ratio) of 15.04.

      Gilead Sciences (GILD) Options Flow Summary

      GILD Options Flow

      Overall Flow

      Bullish

      Net Premium

      400k

      Calls / Puts

      300.00%

      Buys / Sells

      71.43%

      OTM / ITM

      50.00%

      Sweeps Ratio

      0.00%

      GILD Latest News

      More News

      FeaturedBNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth

      18 hours ago

      EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA PRÉVENTION DU VIH

      EFFICACITÉ DE 100 % ET SUPÉRIORITÉ AVÉRÉES DU LÉNACAPAVIR DE GILEAD UTILISÉ DEUX FOIS PAR AN PAR RAPPORT À TRUVADA (MD) UNE FOIS PAR JOUR POUR LA...

      June 26 2024
      PR Newswire (Canada)

      Honeywell Acquires CAES Systems for $1.9 Billion, Sarepta Therapeutics Surges 34%, Gilead Continues Gains

      Honeywell (NASDAQ:HON) – Honeywell announced the acquisition of CAES Systems for $1.9 billion, focusing on expanding its aerospace and defense technology operations. Under the leadership of...

      June 21 2024
      IH Market News

      Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention

      – First Phase 3 HIV Prevention Trial Ever to Show Zero Infections – – Independent Data Monitoring Committee Recommended That Gilead Stop the Blinded Phase of the PURPOSE 1 Trial at Interim...

      June 20 2024
      Business Wire

      Goldman Sachs Raises S&P 500 Forecast for 2024; Disney Secures Deadpool & Wolverine in Chinese Cinemas, and More

      Walt Disney (NYSE:DIS) – Disney managed to secure the release of Deadpool & Wolverine in Chinese cinemas in July, after previous restrictions. This move increases Disney’s revenue...

      June 17 2024
      IH Market News

      New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment

      – Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis to Infusion vs. Third-Line+ Treatment – –...

      June 14 2024
      Business Wire

      Form 4 - Statement of changes in beneficial ownership of securities

      June 11 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 11 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 11 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 11 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-2.22-3.1426953567470.6471.483167.58744049969.01829414CS
      44.887.6802014479163.5472.1862.685940014867.39569434CS
      12-0.74-1.0699826489369.1672.1862.07779357866.63843562CS
      26-12.49-15.436905203380.9187.86562.07759869971.71280631CS
      52-7.835-10.274736082976.25587.86562.07670467874.25575805CS
      156-0.96-1.3836840588169.3889.7457.165716730271.56221537CS
      260-0.22-0.32051282051368.6489.7456.56834975770.31258601CS

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      RDZNRoadzen Inc
      $ 2.95
      (82.10%)
      		108.01M
      SYTSYLA Technologies Company Ltd
      $ 3.05
      (59.69%)
      		6.19M
      VSVersus Systems Inc
      $ 1.90
      (43.94%)
      		58.92M
      VIVKVivakor Inc
      $ 3.41
      (36.95%)
      		727.57k
      MEDSTRxADE HEALTH Inc
      $ 18.585
      (30.70%)
      		397.66k
      MAXNMaxeon Solar Technologies Ltd
      $ 0.18
      (-67.20%)
      		173.94M
      RNACCartesian Therapeutics Inc
      $ 15.7715
      (-35.02%)
      		1.45M
      EFTReFFECTOR Therapeutics Inc
      $ 0.18
      (-32.56%)
      		1.63M
      DTSSDatasea Inc
      $ 3.43
      (-30.57%)
      		1.15M
      ARDXArdelyx Inc
      $ 5.29
      (-30.12%)
      		22.67M
      NVDANVIDIA Corporation
      $ 122.67
      (-1.31%)
      		220.38M
      TSLATesla Inc
      $ 231.26
      (10.20%)
      		205.05M
      MAXNMaxeon Solar Technologies Ltd
      $ 0.18
      (-67.20%)
      		173.94M
      SQQQProShares UltraPro Short QQQ
      $ 7.88
      (-2.96%)
      		114.59M
      RDZNRoadzen Inc
      $ 2.95
      (82.10%)
      		108.01M

      GILD Discussion

      View Posts
      north40000 north40000 3 weeks ago
      https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174602784

      "Gilead plans to share new preclinical data for an oral GLP-1 at the upcoming American Diabetes Association conference starting June 21… The asset, dubbed GS-4571, has previously demonstrated 5% to 8% weight loss in monkeys in 28 to 30 days…"
      👍️0
      north40000 north40000 3 weeks ago
      How about oral GLP-1 news? CNBC-TV AH today. Portal Innovations CEO interview.
      👍️0
      jondoeuk jondoeuk 1 month ago
      There is barely any move on this news. Seems the market had already written it off. O'Day needs to go, they need to rebuild in areas they have expertise in and refocus in oncology.
      👍️0
      jondoeuk jondoeuk 1 month ago
      A double whammy https://www.oncologypipeline.com/apexonco/asco-2024-full-evoke-01-result-adds-gileads-trodelvy-problems
      👍️0
      jondoeuk jondoeuk 1 month ago
      They guided that a third of revenues will be from oncology by 2030...! https://www.businesswire.com/news/home/20240530516266/en/Gilead-Provides-Update-on-Phase-3-TROPiCS-04-Study
      👍️0
      jondoeuk jondoeuk 1 month ago
      ''Using independent datasets, we validate that CD8-fit T cells (1) are present premanufacture and are associated with clinical responses in individuals treated with axicabtagene ciloleucel, (2) longitudinally persist in individuals after treatment with CAR T cells and (3) are tumor migrating cytolytic cells capable of intratumoral expansion in solid tumors.'' https://www.nature.com/articles/s43018-024-00768-3

      https://medicalxpress.com/news/2024-05-cancer-optimal-cells.html
      👍️0
      jondoeuk jondoeuk 1 month ago
      The oNKo-Innate team, along with scientists at Kite, have just published a research article https://onlinelibrary.wiley.com/doi/10.1002/cti2.1507

      Optimised manufacturing dramatically improves lentiviral transduction efficiency of primary human NK cells. The field has progressed greatly with CAR transduction rates in human NK cells (it was ~5% just a few years ago). The oNKo-Innate R&D team were able to raise CAR transduction efficiency to ~80%. After testing various NK cell sources, they conclude that the exponential expansion pre- and post-transduction and high on-target cytotoxicity make PB-derived NK cells a feasible and attractive CAR-NK cell product for clinical utility.

      ''No doubt CAR-NK cells have faced several challenges in oncology settings, and we hope our new findings assist researchers in addressing some of these challenges while also improving the potential for CAR-NK cell therapies in treating autoimmune disease such as lupus'' said Nicholas Huntington, PhD, oNKo-innate's CSO.
      👍️0
      jondoeuk jondoeuk 2 months ago
      The management has been substandard for many years https://www.fiercebiotech.com/biotech/gilead-gives-49b-antibody-solid-tumor-plan-unravels and https://www.fiercepharma.com/pharma/gilead-writes-24b-trodelvy-ceo-underscores-time-focused-execution
      👍️0
      jondoeuk jondoeuk 3 months ago
      IL-12 is the new IL-2! https://www.oncologypipeline.com/apexonco/xilio-gets-gilead-shaped-reprieve
      👍️0
      jondoeuk jondoeuk 3 months ago
      Interesting (preclinical) data from another company. It summarises two distinct phenotypes of cells within the product (they are manufacturing), each of which plays a different role in responding to cancer cells. Each cell population were separated based on whether they produced CD4 on their surface (CD4+ vs. CD4-). Cells negative for CD4 (CD4-) were better able to kill target cancer cells via the CD19 CAR. In contrast, CD4+ cells proliferated faster in response to CD19+ cancer cells. The two groups of cells also produced a different cytokine response in response to CAR activation.
      👍️0
      jondoeuk jondoeuk 4 months ago
      Kite Analyst & Investor Event https://s29.q4cdn.com/585078350/files/doc_events/2024/Mar/14/gild_kite-analyst-investor-event-14-march-2024.pdf
      👍️0
      jondoeuk jondoeuk 4 months ago
      I found the poster, but nothing on the design of the CARs, data on ex vivo expansion, or the percentage of CD62L+ NKTs https://www.jci.org/articles/view/83476 https://journals.aai.org/jimmunol/article/201/7/2141/107140/IL-21-Selectively-Protects-CD62L-NKT-Cells-and
      👍️0
      jondoeuk jondoeuk 4 months ago
      Some more https://www.abstractsonline.com/pp8/#!/20272/presentation/10568
      👍️0
      Monksdream Monksdream 5 months ago
      GILD new 52 week high
      👍️0
      jondoeuk jondoeuk 7 months ago
      Preclinical API-192 data https://ash.confex.com/ash/2023/webprogram/Paper181271.html

      It is a first-in-class OTS CAR-NKT cell therapy that expresses dual CARs (targeting CD19 and CD20) and sIL-15. API-192 is the first development candidate out of a '21 collaboration and license agreement with Kite.
      👍️0
      jondoeuk jondoeuk 8 months ago
      Another next-gen collab https://www.businesswire.com/news/home/20231030344859/en/Kite-and-Epic-Bio-Announce-Collaboration-to-Develop-New-Therapies-for-Cancer

      There have been a number of these over the years, but nothing seems to come of them
      👍️0
      jondoeuk jondoeuk 8 months ago
      The ACLX partnership looks like it could be be a gold mine. The ASH data completely dooms TSVT https://ash.confex.com/ash/2023/webprogram/Paper189761.html

      If Breyanzi can't take share from Yescarta, Abecma doesn't stand a chance. They made sure to point out how Carvytki is giving some Parkinsonian-like events where they have not seen it (yet). Carvykti vs ddBCMA is going to be a battle down the road.
      👍️0
      Greedy G Greedy G 10 months ago
      ~bought 9/22 $80 calls .08c
      👍️0
      jondoeuk jondoeuk 1 year ago
      Q1 results https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171789595
      👍️0
      DewDiligence DewDiligence 1 year ago
      Why is an oral prodrug of Remdesivir anything to get excited about?
      👍️0
      jondoeuk jondoeuk 1 year ago
      Obeldesivir (an oral prodrug of remdesivir) https://news.yahoo.com/gilead-details-promising-early-covid-223448308.html
      👍️0
      jondoeuk jondoeuk 1 year ago
      Kite just released ZUMA-7 results for 2L https://www.businesswire.com/news/home/20230320005701/en/Kite%E2%80%99s-Yescarta%C2%AE-CAR-T-cell-Therapy-Demonstrates-a-Statistically-Significant-Improvement-in-Overall-Survival-for-Initial-Treatment-of-RelapsedRefractory-Large-B-cell-Lymphoma

      What's big is that the trial reached five year maturity instead of just the number of deaths. Looking at it, more than 210 of the 359 (58%) are still alive at five years compared to 43% in ZUMA-1 (3L+). Sure, these were healthier patients, but the CR rate was more double (65% vs. 32%) against the standard of care. So, treatment works better in healthier patients. ZUMA-23 in 1L (against R-CHOP) is ongoing.

      The next question is whether treating healthier patients with multiple myeloma (if they can resolve supply issues with auto) can (significantly) improve PFS.
      👍️0
      fink fink 2 years ago
      Christmas sell off over, last day to lock in any paper tax loss. LOL

      Who’s losing money here?

      I think we start the trend back up into Q1
      👍️0
      fink fink 2 years ago
      It wants $90.
      I got a sell order in @88, but think it will continue up.
      Gilead is moving away from HIV and more into this cancer thingy.

      That’s not enough in my mind to justify the rise. But I do think as World central banks default and the Fed starts to absorb these other world bank’s debt on foreign currency collapse, private money has to go somewhere safe. Pharma has always been recession proof. Gilead was a great stock to load. Like LNG was 7 years ago. No end is sight there too

      Gilead still needs revenue from its new cancer avenues. HIV, they own and always will. Just already built into the $60 stock price
      👍️0
      PennyPusher786 PennyPusher786 2 years ago
      It's at a 3 year high
      👍️0
      fung_derf fung_derf 2 years ago
      Very funny that you posted this to me. I couldn't recall, but knew there were a couple of you who followed me over here. It has had a pretty nice month.

      I_luv_cydy

      Re: fung_derf post# 3875

      Tuesday, May 19, 2020 2:32:23 PM

      Post#
      3878
      of 4839
      Fung: Why do you suppose GILD keeps dropping? I'm a shareholder for a while.
      👍️0
      fink fink 2 years ago
      Nice to see GILD over $80

      Wonder if I should trim some? It’s been eating chit pie for some time.
      Still don’t see why the spike.
      👍️0
      jondoeuk jondoeuk 2 years ago
      Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers https://www.businesswire.com/news/home/20221020005633/en/Kite-and-Refuge-Biotechnologies-Announce-Exclusive-License-Agreement-for-Investigational-Gene-Expression-Platform-for-Blood-Cancers

      Some preclinical data from Refuge Bio https://jitc.bmj.com/content/8/Suppl_3/A86.2 https://jitc.bmj.com/content/9/Suppl_2/A162 https://jitc.bmj.com/content/9/Suppl_2/A164 https://jitc.bmj.com/content/8/Suppl_3/A458.2
      👍️0
      Zeppo Zeppo 2 years ago
      Gilead has underperformed for so long, given the size of the company as well, that I could encourage Bill Ackman to make a run at it.
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD details why the purportedly-positive Trodelvy data from Mar 2022 weren’t:

      https://www.businesswire.com/news/home/20220603005437/en The study met its primary endpoint of progression-free survival (PFS) with a statistically significant and clinically meaningful 34% reduction in the risk of disease progression or death (median PFS 5.5 vs. 4 months; HR: 0.66; 95% CI: 0.53-0.83; P<0.0003). The first interim analysis of the key secondary endpoint of overall survival (OS) demonstrated a trend in improvement. In this context, a “trend in improvement” means non-statsig. OS could conceivably turn statsig in a later data cut, but that’s pretty unlikely.

      The viewpoint in #msg-158260565 (from 2020) has not changed.
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      59.77 ? -1.79 (-2.91%)
      Volume: 10,483,423 @04/29/22 7:42:23 PM EDT
      Bid Ask Day's Range
      59.53 60.0 59.27 - 62.06
      GILD Detailed Quote
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-11. Improved CAR-T responses with 4-1BB agonist utomilumab added to axi-cel. The cells were more of central and effector phenotype. No (S)AE concerns.




      👍️0
      jondoeuk jondoeuk 2 years ago
      Link to the audio recording https://investors.gilead.com/events/event-details/gilead-sciences-oncology-deep-dive
      👍️0
      jondoeuk jondoeuk 2 years ago
      Oncology Deep Dive https://investors.gilead.com/static-files/332d0c81-fa18-44fa-82d3-babf96ca12d0

      https://endpts.com/with-more-than-30-oncology-partners-gilead-lays-out-its-2030-vision-of-20-new-approvals/
      👍️0
      jondoeuk jondoeuk 2 years ago
      ZUMA-12 https://www.nature.com/articles/s41591-022-01731-4

      The CR rate was higher than standard frontline chemo, with just a single treatment vs. six cycles over about four months.

      No reason to think long-term curve won't flatten like ZUMA-1 (which was post ~two years).

      PDUFA date (for 2nd line) is April 1.
      👍️0
      mick mick 2 years ago
      GILD News: Gilead price target slashed at Barclays following new Trodelvy data 03/10/2022 05:38:07 AM
      GILD News: Current Report Filing (8-k) 03/07/2022 03:31:07 AM
      GILD News: Phase 3 TROPiCS-02 Study Met the Primary Endpoint of Progression-Free Survival in Late-Line HR+/HER2- Metastatic Breast Cancer 03/07/2022 03:30:00 AM
      GILD News: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD) 03/03/2022 12:10:51 AM
      GILD News: Jefferies Thinks Gilead Sciences’ Stock is Going to Recover 03/02/2022 03:35:55 AM
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      58.39 ? 0.47 (0.81%)
      Volume: 13,007,627 @03/11/22 7:41:31 PM EST
      Bid Ask Day's Range
      58.2 58.4 57.955 - 59.185
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      61.33 ? 0.22 (0.36%)
      Volume: 9,751,206 @02/15/22 4:17:32 PM EST
      Bid Ask Day's Range
      61.15 61.33 60.97 - 61.515
      GILD Detailed Quote
      👍️0
      mick mick 2 years ago
      Gilead Sciences Inc (GILD)
      63.9 ? -1.49 (-2.28%)
      Volume: 12,392,843 @02/04/22 7:58:42 PM EST
      Bid Ask Day's Range
      63.8 64.0 63.8722 - 65.61
      GILD Detailed Quote
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD owes ViiV* $1.25B+_3% royalty on_US Biktarvy sales, as a result of a patent settlement:

      https://www.gsk.com/en-gb/media/press-releases/gsk-announces-settlement-between-viiv-healthcare-and-gilead-sciences/

      The 3% royalty is a pretty big deal since Biktarvy’s had annualized US sales of $8.4B(!) in 4Q21.

      * ViiV is a JV comprised of: GSK (76.5%); PFE (13.5%); and Shionogi (10%).
      👍️0
      DewDiligence DewDiligence 2 years ago
      GILD 4Q21 results…

      PR:
      https://investors.gilead.com/static-files/107ab0e3-735c-4760-882f-c3647ea97ce2

      CC slides:
      https://investors.gilead.com/static-files/afa262c5-7eed-4944-81f5-3c2d09489d1b
      👍️0
      mick mick 2 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      DewDiligence DewDiligence 3 years ago
      GILD vs BMY in LBCL CAR-T—who has the edge?

      https://www.fiercepharma.com/pharma/bristol-myers-squibb-breyanzi-gilead-yescarta-lock-horns-car-t-therapy-earlier-lymphoma

      Both Yescarta and Breyanzi are poised to take share from stemcell transplants.
      👍️0
      mick mick 3 years ago
      https://www.otcmarkets.com/stock/GILD
      👍️0
      dhbuzz dhbuzz 3 years ago
      GILD and MTNB have been working on ORAL remdesivir ,results to date look outstanding ,if this is green lighted by FDA,should really give GILD a SP jump as well as MTNB

      GLTA
      👍️0
      DewDiligence DewDiligence 3 years ago
      VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

      https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

      I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

      Please see #msg-160854272 for background.
      👍️0
      Michel Michel 3 years ago
      I Agree: https://www.griproom.com/fun/pfizers-covid-pill-might-not-be-as-great-as-theyre-saying


      Brilacidina y Remdesivir
      👍️0
      Ultimate01 Ultimate01 3 years ago
      Showtime this week! Brilacidin is a BEAST. Remdesivir needs Brilicidin to remain relevant and in the market but Brilacidin does not need Remdesivir. Gilead has the opportunity to remain relevant and go down in history as the company that helped end the pandemic, or the company that missed the greatest opportunity.
      👍️0
      mick mick 3 years ago
      Gilead Sciences Inc (GILD)
      66.68 ? 0.21 (0.32%)
      Volume: 6,519,261 @11/05/21 7:59:38 PM EDT
      Bid Ask Day's Range
      66.16 66.68 65.76 - 66.87
      GILD Detailed Quote
      👍️0
      mick mick 3 years ago
      i think so they got ah good pipeline though
      👍️0

      Your Recent History

      NASDAQ
      GILD
      Gilead Sciences
      Delayed Upgrade Clock